{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457123959
| image =

<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu
| target = [[SLAMF7]] (CD319)

<!-- Clinical data -->
| tradename = Empliciti
| pregnancy_AU =
| pregnancy_US = X
| pregnancy_category = X (used with [[lenalidomide]])
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US = ℞-only
| legal_status =
| routes_of_administration = [[Intravenous therapy|IV]]

<!-- Pharmacokinetic data -->
| bioavailability = 100% (IV)
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 915296-00-3
| ATC_prefix = L01
| ATC_suffix = XC23
| PubChem =
| IUPHAR_ligand = 8361
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB06317
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1351PE5UGS

<!-- Chemical data -->
| C=6476 | H=9982 | N=1714 | O=2016 | S=42
| molecular_weight = 145.5 kg/mol
}}

'''Elotuzumab''' (brand name '''Empliciti''', previously known as '''HuLuc63''') is a [[humanized monoclonal antibody]] used in relapsed [[multiple myeloma]].<ref name=FDA>{{cite web|title=Press Announcement—FDA approves Empliciti, a new immune-stimulating therapy to treat multiple myeloma|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm|website=U.S. Food and Drug Administration|accessdate=3 December 2015}}</ref>  The package insert denotes its mechanism as a [[SLAMF7]]-directed (also known as CD 319) immunostimulatory antibody.<ref name=PI>{{cite web|title=Empliciti (elotuzumab) for Injection, for Intravenous Use. Full Prescribing Information |url=http://packageinserts.bms.com/pi/pi_empliciti.pdf |website=Empliciti (elotuzumab) for US Healthcare Professionals |publisher=Bristol-Myers Squibb Company|location=Princeton, New Jersey|deadurl=yes |archiveurl=https://web.archive.org/web/20151208064304/http://packageinserts.bms.com/pi/pi_empliciti.pdf |archivedate=2015-12-08 |df= }}</ref>

==Approvals and indications==
===Multiple myeloma===
In May 2014, it was granted "[[Breakthrough Therapy]]" designation by the [[Food and Drug Administration|FDA]] (for multiple myeloma).<ref>{{cite press release |url=http://news.bms.com/press-release/rd-news/bristol-myers-squibb-and-abbvie-receive-us-fda-breakthrough-therapy-designatio |title=Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma |location=Princeton, New Jersey and North Chicago, Illinois |date=2014-05-19 |accessdate=2015-02-05 |publisher=Bristol-Myers Squibb}}</ref> On November 30, 2015, FDA approved elotuzumab as a treatment for patients with multiple myeloma who have received one to three prior medications.<ref name=FDA/> Elotuzumab was labeled for use with [[lenalidomide]] and [[dexamethasone]]. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, [[diphenhydramine]], [[ranitidine]] and [[acetaminophen]].<ref name=PI/> In May 2016 the EC/EU gave a similar approval.<ref>[http://www.pmlive.com/pharma_news/bms_gets_two_new_cancer_approvals_in_europe_1021270 BMS gets two new cancer approvals in Europe. May 2016]</ref>

==References==
{{Reflist}}

==External links==
* [http://www.empliciti.com Empliciti (elotuzumab) Official Web Site]

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Breakthrough therapy]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}